REFERENCES
- Glassman A, Chalkidou K, Giedion U, Teerawattananon Y, Tunis S, Bump JB, Pichon-Riviere A. Priority-setting institutions in health: recommendations from a Center for Global Development Working Group. Global Heart 2012; 7(1): 13-34.
- Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health 2012; 15(8): 1172-1181.
- Dakin H, Devlin N, Feng Y, Rice N, O'Neill P, Parkin D. The influence of cost-effectiveness and other factors on NICE decisions. Health Econ 2015; 24(10): 1256-1271.
- Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ 2015; 24(10): 1287-1301.
- World Health Organization. Cost-effectiveness thresholds. n.d. Available at http://www.who.int/choice/costs/CER_thresholds/en/ (accessed 18 October 2015)
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. April 2013. Available at http://publications.nice.org.uk/pmg9 (accessed 19 October 2015)
- Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015; 19(14): 1-503.
- Barnsley P, Towse A, Karlsberg Schaffer S, Sussex J. Critique of CHE Research Paper 81: methods for the estimation of the NICE Cost Effectiveness Threshold. London, UK: Office of Health Economics; 2013.
- Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. CHE Research Paper 109. York, UK: University of York; 2015.
- Chalkidou K. Evidence and values: paying for end of life drugs in the British NHS. Health Econ Policy Law 2012; 7(4): 393-409.
- Shah K. Valuing health at the end of life. 2015. Available at https://www.ohe.org/news/valuing-health-end-life-review-empirical-literature (accessed 5 November 2015)
- van de Wetering EJ, Stolk EA, van Exel NJA, Brouwer WBF. Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. Eur J Health Econ 2013; 14(1): 107-115.
- Departementenes sikkerhets- og serviceorganisasjon. Åpent og rettferdig—prioriteringer i helsetjenesten [Open and fair - priorities in health]. Norges offentlige utredninger, Oslo, Norway; 2014: 1-218.
- Department of Health. Methodology for estimating “wider societal benefits” as the net production impact of treatments. 2013. Available at https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/DH-Documentation-for-Wider-Societal-Benefits.pdf (accessed 19 October 2015)
- Culyer AJ, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy 2007; 12(1): 56-58.
- Revill P, Walker S, Madan J, Ciaranello A, Mwase T, Gibb DM, Claxton K, Sculpher M. Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: are current international norms fit for purpose? CHE Research Paper 98. York, UK: University of York; 2014.
- Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics 2014; 32(6): 525-531.
- McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26(9): 733-744.
- Basu A. Irrelevance of explicit cost—effectiveness thresholds when coverage decisions can be reversed. Expert Rev Pharmacoecon Outcomes Res 2013; 13(2): 163-165.
- McGuire A, Drummond M, Martin M, Justo N. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes? Expert Rev Pharmacoecon Outcomes Res 2015; 15(4): 599-605.